- Conditions
- Carcinoma, Non Small Cell Lung (NSCLC)
- Interventions
- Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,629
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chemotherapy, Computed Tomography, Cytarabine, Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 11
- States / cities
- Rochester, Minnesota • St Louis, Missouri • New York, New York + 7 more
- Conditions
- Plasma Cell Leukemia
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 7
- States / cities
- Middletown, New Jersey • Montvale, New Jersey • Buffalo, New York + 4 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Usual Care, Intervention Arm
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Lewes, Delaware • Savannah, Georgia • Chicago, Illinois + 7 more
- Conditions
- Cancer, Malignant Neoplasm
- Interventions
- Bioelectrical impedance Analysis (BIA), D3-Creatine Dilution (D3Cr), 6-Minute Walk Test (6MWT), Timed Up and Go (TUG), 30-second Sit-to-Stand (STS), Hand Grip Strength (GS), PBTL p16 expression, CT, MR and PET Imaging
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
- Drug · Biological · Radiation + 2 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8
- Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Positron Emission Tomography, Tumor Resection
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 8 more
- Conditions
- Brain Cancer, Brain Stem Glioma
- Interventions
- Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- Y-mAbs Therapeutics
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography, Computed Tomography, Electronic Health Record Review
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cardiac Sarcoidosis
- Interventions
- 68Ga-DOTATATE PET/CT, 18FDG PET/CT scan, 13NH3 PET/CT scan
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Biopsy, Biospecimen Collection, Computed Tomography, Golimumab, Magnetic Resonance Imaging, PSMA PET Scan, Bone Scan
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Carcinoma, Renal Cell, Kidney Neoplasms
- Interventions
- 18F-VM4-037, PET/CT
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Interventions
- Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Recurrent AL Amyloidosis, Refractory AL Amyloidosis
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Dexamethasone, Echocardiography Test, Ixazomib Citrate, Magnetic Resonance Imaging, Positron Emission Tomography, Transabdominal Ultrasound, Venetoclax, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 16
- States / cities
- Duarte, California • Sacramento, California • Atlanta, Georgia + 10 more
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hodgkin Disease, Myelodysplastic Syndromes, Multiple Myeloma
- Interventions
- CD34-TK75 transduced donor lymphocytes, Sub Study - 18 FHBG PET/CT Scans
- Genetic · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Coronary Artery Disease
- Interventions
- Myocardial perfusion imaging
- Procedure
- Lead sponsor
- Aspire Foundation
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
- Interventions
- Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Other · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Alzheimer Disease, Sleep Apnea
- Interventions
- PET Scan and nocturnal polysomnography
- Diagnostic Test
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Down Syndrome, Alzheimer's Dementia
- Interventions
- biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
- Procedure · Other
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Drug Effects
- Interventions
- [11C] desmethyl-loperamide, Control - no pretreatment, Oral ritonavir, Oral efavirenz
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
- Drug · Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Deep Venous Thrombosis, Post-thrombotic Syndrome
- Interventions
- PET/CT
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
- Interventions
- oncolytic measles virus encoding thyroidal sodium iodide symporter, laboratory biomarker analysis, single photon emission computed tomography, computed tomography
- Biological · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota